Replimune (Nasdaq: REPL), a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering.
The proceeds are expected to support Replimune’s ongoing development of its RPx platform and expand its pipeline, which is focused on treatments for solid tumors.
The latest haul will add to significant fundraising efforts since the firm was founded in 2015, including a record $320 million private financing round in its early years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze